CTE Sessions at EANM’09

EANM’09 – CTE Session II

October 12, 2009, 08:00 – 09:30
Clinical Brain PET/CT Scanning – The Near Future

Moderator: K. Perdersen (Copenhagen)
Co-Moderator: M. Freixinet (Barcelona)


Speakers
extended
abstract
B. Dall (Copenhagen):
Technical and Psychological Aspects regarding Patient Preparation, and Perfoming High Quality Brain PET Scanning in Patients with Brain Tumours, Dementia and Epilepsy
I. Law (Copenhagen):
Clinical Brain PET/CT Scanning beyond FDG


Educational objectives:

Upon completion of this session the attendee will have an understanding of:

  1. Understand the technologist’s role in the physical and psychological aspects regarding patient preparation for brain PET/CT scanning.
  2. Understand and explain the role of 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) in brain tumors.
  3. Understand and explain the use of amyloid binding tracers for dementia (for example [11C]-PiB), Amino acid analogues (for example [18F]-FET) and Somatostatin 2 receptor binding ligands ([68Ga]-DOTATOC).

Patient preparation for brain PET/CT scanning, and technical and psychological aspects regarding patient preparation: Performing high quality brain PET scanning in patients with brain tumours, dementia and epilepsy.

The role of 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) in brain tumours and alternative PET tracers: The presentation will address some of the limitations of using FDG for clinical brain PET scanning, and present a number of alternative PET tracers that could realistically obtain a broader clinical application in the next few years. These include the use of amyloid binding tracers for dementia (e.g. [11C]-PiB), Amino acid analogues (e.g. [18F]-FET), and Somatostatin 2 receptor binding ligands ([68Ga]-DOTATOC).


Summary:

The most widely applied PET tracer is 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) driven primarily by a demand in general oncology. This tracer can readily be applied to a range of clinical questions including brain tumours, and dementia. The presentation will address some of the limitations of using FDG for clinical brain PET scanning, and present a number of alternative PET tracers that could realistically obtain a broader clinical application in the next few years. These include the use of amyloid binding tracers for dementia (e.g. [11C]-PiB), Amino acid analogues (e.g. [18F]-FET), and Somatostatin 2 receptor binding ligands ([68Ga]-DOTATOC).

Back to top